Sawai Group Holdings Co., Ltd. (TYO:4887)

Market Cap	226.34B
Revenue (ttm)	189.02B
Net Income (ttm)	11.97B
Shares Out	115.45M
EPS (ttm)	96.24
PE Ratio	112.22
Forward PE	12.90
Dividend	55.00 (2.82%)
Ex-Dividend Date	Sep 29, 2025

Volume	311,500
Average Volume	375,875
Open	1,949.50
Previous Close	1,949.50
Day's Range	1,949.50 - 1,983.50
52-Week Range	1,650.00 - 2,250.00
Beta	-0.03
RSI	66.39
Earnings Date	Aug 12, 2025

About HashiCorp

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 3,310
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4887

Financial Performance

In 2024, Sawai Group Holdings's revenue was 189.02 billion, an increase of 6.88% compared to the previous year's 176.86 billion. Earnings were 11.97 billion, a decrease of -12.60%.